Gene alterations associated with response to anthracycline therapy for breast cancer

[News]

Alterations in the topoisomerase II alpha (TOP2A) gene were associated with better patient outcomes following anthracycline-based therapy compared with non-anthracycline-based regimens, according to a study in the April 28 online issue of the Journal of the National Cancer Institute.

More... (http://www.news-medical.net/?id=49016)